Get the Stockscreener App
2.09
0.10%
-0.002
Pre-market:
2.03
-0.06
-2.87%
Revelation Biosciences Inc stock is traded at $2.09, with a volume of 1.37M.
It is down -0.10% in the last 24 hours and down -39.24% over the past month.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
See More
Previous Close:
$2.092
Open:
$2
24h Volume:
1.37M
Relative Volume:
2.80
Market Cap:
$3.10M
Revenue:
-
Net Income/Loss:
$-15.52M
P/E Ratio:
-0.1125
EPS:
-18.58
Net Cash Flow:
$-16.61M
1W Performance:
-37.80%
1M Performance:
-39.24%
6M Performance:
-80.58%
1Y Performance:
-87.68%
1-Day Range:
$1.85
$2.32
1-Week Range:
$1.85
$5.80
52-Week Range:
$1.85
$18.80
Revelation Biosciences Inc Stock (REVB) Company Profile
Name
Revelation Biosciences Inc
Sector
Industry
Phone
650-800-3717
Address
4660 LAJOLLA VILLAGE DRIVE, SAN DIEGO
Compare REVB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
REVB
Revelation Biosciences Inc
|
2.09 | 774.58K | 0 | -15.52M | -16.61M | -18.58 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.91 | 120.31B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
751.13 | 81.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
846.75 | 53.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
349.58 | 46.87B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
350.00 | 37.20B | 4.98B | 69.59M | 525.67M | 0.5197 |
Revelation Biosciences Inc Stock (REVB) Latest News
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - cantonrep.com
US Market Recap: Whats the beta of Revelation Biosciences Inc stock2025 Volume Leaders & Stepwise Entry and Exit Trade Signals - baoquankhu1.vn
REVB Stock Drops 10% After Company Announces Third Reverse Split In A Year - Asianet Newsable
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development - the-daily-record.com
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds - chronicle-tribune.com
Revelation Biosciences to implement 1-for-4 reverse stock split By Investing.com - Investing.com Nigeria
Revelation Biosciences to Implement 1-for-4 Reverse Stock Split - marketscreener.com
Revelation Biosciences to implement 1-for-4 reverse stock split - Investing.com
Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026 - kansascity.com
Revelation Biosciences to combine 4 shares into 1 for Nasdaq bid - Stock Titan
Can Revelation Biosciences Inc. expand into new marketsMarket Trend Report & Free AI Powered Buy and Sell Recommendations - mfd.ru
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026) - citizen-times.com
Revelation Biosciences announces warrant exercise agreement By Investing.com - Investing.com Australia
Revelation Biosciences, Inc. (REVB) stock: plunges 24% after massive warrant dilution deal - parameter.io
Revelation Biosciences announces warrant exercise agreement - Investing.com
Revelation Biosciences trades new 5-year warrants for $11M cash - Stock Titan
Revelation Biosciences Gains Momentum as FDA Agreement Sparks Hope - StocksToTrade
Revelation Biosciences (REVB) stock ticks up premarket after FDA lays out Gemini trial path - TechStock²
Stock Market Today: S&P 500, Dow Jones, Nasdaq 100 Futures Decline After 2 Consecutive Days Of Gains—Intel, CSX In Focus (UPDATED) - Benzinga
Revelation Biosciences (REVB) Secures FDA Agreement for Gemini Drug's Clinical Trial Pathway - Intellectia AI
Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours? - Benzinga
Revelation Biosciences reaches FDA agreement on AKI treatment pathway By Investing.com - Investing.com Nigeria
Revelation Biosciences Reaches FDA Agreement on Gemini for AKI - TradingView
Targets Report: What is Revelation Biosciences Inc. Equity Warrant’s valuation compared to sectorWeekly Trade Report & Long Hold Capital Preservation Tips - baoquankhu1.vn
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI - lansingstatejournal.com
Revelation Biosciences reaches FDA agreement on AKI treatment pathway - Investing.com
FDA, Revelation map single trial for deadly kidney injury drug - Stock Titan
Will Revelation Biosciences Inc. Equity Warrant benefit from green energy policiesDay Trading Setups & Free Unlock Rapid Growth Potential - bollywoodhelpline.com
Will Revelation Biosciences Inc. Equity Warrant be affected by tariffsDollar Strength & Low Drawdown Investment Ideas - bollywoodhelpline.com
How Revelation Biosciences Inc. stock trades before earningsMarket Trend Report & Stepwise Entry and Exit Trade Signals - bollywoodhelpline.com
Treasury Yields: Is PLYA likely to announce a buybackJuly 2025 Spike Watch & AI Driven Price Forecasts - baoquankhu1.vn
Trend Recap: Is Revelation Biosciences Inc Equity Warrant backed by strong institutional buyingJuly 2025 Outlook & Reliable Entry Point Alerts - baoquankhu1.vn
Revelation Biosciences Inc Stock (REVB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.49%
4.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):